Polymyositis with confirmed muscle involvement (myopathy), classified under the dermatopolymyositis category of systemic connective tissue disorders.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 5
- Region
- General
Documentation tips
What should appear in the chart to support M33.22.
Source · Editorial brief grounded in 5 cited references ↓
- Explicitly state 'polymyositis with myopathy' in the assessment — do not leave organ involvement ambiguous, as M33.20 (unspecified) will be assigned without a documented finding.
- Distinguish polymyositis from dermatomyositis in the note; polymyositis lacks the skin findings (heliotrope rash, Gottron's papules) that define dermatomyositis, and the two map to different ICD-10 codes.
- Document objective evidence of myopathy: proximal muscle weakness graded by manual muscle testing, elevated creatine kinase, abnormal EMG findings, or muscle biopsy results — this supports M33.22 over the unspecified sibling codes.
- If respiratory involvement is also present, evaluate whether M33.21 or an additional respiratory code is warranted; M33.22 captures myopathy as the primary feature, not respiratory manifestations.
- Note any immunosuppressive or corticosteroid therapy in the plan, as payer audits for inflammatory myopathy diagnoses often look for treatment consistency with the stated diagnosis.
Related CPT procedures
Procedure codes commonly billed with M33.22. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M33.22 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning M33.20 (organ involvement unspecified) when myopathy is clearly documented — always code to the highest level of specificity supported by documentation.
- Using M33.22 for dermatomyositis with myopathy — that maps to M33.12; check the attending's diagnosis language carefully before assigning the polymyositis subcategory.
- Confusing M33.22 with neurological myopathy codes (G72.x or G73.7) — M33.22 is specific to idiopathic inflammatory polymyositis; neurologic or drug-induced myopathies belong elsewhere in the tabular.
- Failing to code coexisting manifestations separately when instructed — review the M33 category notes for any 'code also' or 'use additional code' instructions that may apply to associated conditions such as pulmonary fibrosis.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M33.22 is the correct code when a patient carries a confirmed diagnosis of polymyositis and the encounter documentation explicitly establishes myopathy — that is, measurable muscle weakness or dysfunction attributable to the inflammatory muscle disease. Within the M33.2 subcategory, the 5th character distinguishes the dominant organ system involved: use M33.20 when organ involvement is unspecified, M33.21 when respiratory involvement is the feature, M33.22 when myopathy is the documented finding, and M33.29 for other organ involvement. Do not default to M33.20 when myopathy is clearly documented — that's a specificity loss that can affect DRG assignment.
Polymyositis falls under the broader M33 category (Dermatopolymyositis), which also includes juvenile dermatomyositis (M33.0x), other dermatomyositis (M33.1x), and unspecified dermatopolymyositis (M33.9x). M33.22 applies only to polymyositis, not dermatomyositis with myopathy — that maps to M33.12. The distinction matters: polymyositis lacks the cutaneous features of dermatomyositis and the two are clinically and coding-distinct entities. In the inpatient setting, M33.22 groups to MS-DRG 545 (with MCC), 546 (with CC), or 547 (without CC/MCC) under the connective tissue disorders DRG family.
Because polymyositis is an idiopathic inflammatory myopathy (IIM), it is typically managed by rheumatology, but orthopedic practices may encounter it as a secondary or complicating diagnosis — particularly when patients present with proximal limb weakness, muscle pain, or functional impairment that initially appears musculoskeletal. If polymyositis is a coexisting condition influencing orthopedic management, code it alongside the primary orthopedic diagnosis.
Sibling codes
Other billable codes under M33.2 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01What is the difference between M33.22 and M33.12?
02Can M33.22 be used if myopathy is suspected but not confirmed?
03Should M33.22 be coded as primary or secondary in an orthopedic encounter?
04What MS-DRGs does M33.22 map to in the inpatient setting?
05Is M33.22 ever used with a 7th-character extension?
06What code do I use if the documentation says polymyositis but doesn't specify organ involvement?
07Are there any Excludes1 or Excludes2 notes I need to watch at the M33 category level?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective October 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M33-/M33.22
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M33.22
- 04pmc.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12547942/
- 05cms.govhttps://www.cms.gov/medicare/coding-billing/icd-10-codes
Mira AI Scribe
Mira AI Scribe captures the clinician's explicit characterization of muscle involvement — proximal weakness pattern, CK elevation, EMG results, or biopsy findings — along with the distinction between polymyositis and dermatomyositis (absence of skin involvement). This prevents fallback to M33.20 (organ involvement unspecified), which understates clinical severity and can downgrade DRG assignment or trigger a specificity audit.
See how Mira captures M33.22 documentation